Nurix Therapeutics, Inc. (NRIX) P/E Ratio History
Deep ValueTrading at 6.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, Nurix Therapeutics, Inc. (NRIX) trades at a price-to-earnings ratio of 6.0x, with a stock price of $15.30 and trailing twelve-month earnings per share of $2.54.
The current P/E is 46% below its 5-year average of 11.2x. Over the past five years, NRIX's P/E has ranged from a low of 11.2x to a high of 11.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, NRIX trades at a 76% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, NRIX trades at a notable discount to the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NRIX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NRIX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
NRIX P/E vs Peers
Small-Molecule Cancer Drugs peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $9B | 21.3Lowest | -Best | +1747%Best | |
| $8B | 27.7 | -Best | -148% | |
| $515B | 49.9 | -Best | -1% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
NRIX Historical P/E Data (2026–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | Aug 31 2026 | $25.78 | $2.31 | 11.2x | +0% |
Average P/E for displayed period: 11.2x
NRIX Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NRIX — Frequently Asked Questions
Quick answers to the most common questions about buying NRIX stock.
What is NRIX's P/E ratio?
Nurix Therapeutics, Inc. (NRIX) trailing twelve-month P/E ratio is 6.0x, based on TTM diluted EPS of $2.54. The 5-year average P/E is 11.2x and the historical range spans 11.2x to 11.2x.
Is NRIX stock overvalued or undervalued?
NRIX trades at 6.0x P/E, below its 5-year average of 11.2x. At the 0th percentile of its historical range (11.2x–11.2x), the stock is priced at a discount to its own history.
Is NRIX stock expensive?
No, NRIX is not expensive on a historical basis. The current P/E of 6.0x is below the 5-year average of 11.2x and sits at the 0th percentile of its valuation range.
What is NRIX's historical P/E range?
Over the past 5 years, NRIX's P/E ratio has ranged from 11.2x to 11.2x, with a median of 11.2x and an average of 11.2x. The current P/E of 6.0x places the stock at the 0th percentile of this range. Full historical data spans 2026–2026.
How does NRIX's P/E compare to the S&P 500?
NRIX trades at 6.0x P/E versus the S&P 500 median of 21.8x. The 72% discount to the market suggests lower growth expectations or perceived higher risk.
How does NRIX's valuation compare to Healthcare peers?
Nurix Therapeutics, Inc. P/E of 6.0x compares to the Healthcare sector median of 24.6x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is NRIX's PEG ratio?
NRIX PEG ratio is N/A, based on a P/E of 6.0x and EPS growth of -5.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is NRIX's earnings yield?
NRIX earnings yield is 16.59%, the inverse of its 6.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.